Form 4: Alkermes Executive Sells Shares, Receives Equity Awards

An Alkermes executive sold ordinary shares under a 10b5-1 plan while also receiving new stock options and restricted stock units.

Summary

• David Joseph Gaffin, Executive Vice President and Chief Legal Officer of Alkermes, Inc., reported transactions involving Alkermes plc. ordinary shares.
• Gaffin sold 2,034 ordinary shares on March 2, 2026, at a price of $29.29 per share.
• An additional 2,034 ordinary shares were sold on March 3, 2026, at a price of $29.76 per share.
• These sales were conducted pursuant to a Rule 10b5-1 trading plan adopted by Gaffin on November 19, 2025.
• Following these transactions, Gaffin beneficially owns 235,626 ordinary shares.
• Gaffin was granted 78,292 employee stock options with an exercise price of $30.25 on March 2, 2026.
• These stock options will vest and become exercisable in four equal annual installments, commencing on March 2, 2027, and expire on March 2, 2036.
• Gaffin also received 36,364 restricted stock unit (RSU) awards on March 2, 2026, where each RSU represents a contingent right to receive one ordinary share.
• The RSU awards will vest in four equal annual installments, commencing on March 2, 2027.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive. While there were routine sales under a 10b5-1 plan, the significant grants of new stock options and restricted stock units demonstrate continued executive alignment and long-term incentive.

Positives

• The executive received a significant grant of 78,292 employee stock options, aligning their interests with future company performance.
• The executive was awarded 36,364 restricted stock units, providing a contingent right to receive ordinary shares and further incentivizing long-term commitment.

Negatives

• The executive sold a total of 4,068 ordinary shares, which reduces their direct ownership in the company.

Future Outlook

The executive's newly acquired stock options and restricted stock units are subject to a four-year vesting schedule, commencing on March 2, 2027, indicating a long-term incentive structure tied to future company performance.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures of insider transactions, common for executives managing their equity holdings. The use of a Rule 10b5-1 trading plan for sales is a standard practice to mitigate concerns about insider trading, as it pre-schedules transactions.

Stakeholder Impact

• Shareholders: The executive's sales represent a minor dilution of ownership, but the new equity awards align the executive's long-term interests with shareholder value creation.

Next Steps

• Vesting of 78,292 employee stock options will begin on March 2, 2027, in four equal annual installments.
• Vesting of 36,364 restricted stock unit awards will begin on March 2, 2027, in four equal annual installments.

Key Dates

Keywords

Alkermes, ALKS, Form 4, Insider Trading, Stock Options, Restricted Stock Units, 10b5-1 Plan, Executive Compensation